Who
Ajim Tamboli
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, First Tracks Biotherapeutics; Chief Financial Officer, Monte Rosa Therapeutics.
In numbers
- Trades disclosed
- 16
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 12 Apr 2021
- Last trade
- 12 May 2026
- Last filed
- 14 May 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 May 2026filed 14 May 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,600 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,600 at $0.00 | filing |
| 23 Apr 2026filed 23 Apr 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —41,234 at $0.00 | filing |
| 23 Apr 2026filed 23 Apr 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —41,234 at $0.00 | filing |
| 22 Apr 2026filed 23 Apr 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —41,233 at $0.00 | filing |
| 22 Apr 2026filed 23 Apr 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —41,233 at $0.00 | filing |
| 21 Apr 2026filed 23 Apr 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,700 at $0.00 | filing |
| 21 Apr 2026filed 23 Apr 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —41,233 at $0.00 | filing |
| 21 Apr 2026filed 23 Apr 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,700 at $0.00 | filing |
| 21 Apr 2026filed 23 Apr 2026 | TRAX First Tracks Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —41,233 at $0.00 | filing |
| 3 Jan 2023filed 4 Jan 2023 | GLUE Monte Rosa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —129,850 at $0.00 | filing |
| 1 Mar 2022filed 2 Mar 2022 | GLUE Monte Rosa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —111,700 at $0.00 | filing |
| 23 Jun 2021filed 25 Jun 2021 | GLUE Monte Rosa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —56,649 at $0.00 | filing |
| 12 Apr 2021filed 25 Jun 2021 | GLUE Monte Rosa Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,938 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.